Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
4
days
Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD)
Authors
Longqin HuShow moreShow less
Affiliations
1. Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA; 2. The Cancer Institute of New Jersey, New Brunswick, USAShow moreShow less
56
days
Review of promising benzimidazole-based anticancer agents (2023-2026)
Authors
Elena Y. Shumilova; Sergey V. Sysolyatin; Svetlana V. StrokovaShow moreShow less
Affiliations
1. Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk, RussiaShow moreShow less
58
days
Design, synthesis, biological activity and computational simulation evaluation of pyrimidine-2-aminoacetamide derivatives as cholinesterase inhibitors
Authors
Yi-Xuan Wang; Shi-Hao Qin; Qian Liu; Xue-Wei Zhou; Chao-Yue Zhang; Zheng-Yue MaShow moreShow less
Affiliations
1. College of Pharmaceutical Sciences, Institute of Life Science and Green Development, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Hebei University, Baoding, China; 2. Technology Center of Shijiazhuang Customs District, Baoding, ChinaShow moreShow less
5
days
Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer
Authors
Sumi Lee; Longqin HuShow moreShow less
Affiliations
1. School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea; 2. Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, The State University of New Jersey, 160 Frelinghuy sen Road, Piscataway, Rutgers, USA; 3. The Cancer Institute of New Jersey, New Brunswick, USAShow moreShow less
32
days
Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities
Authors
Meizhen Luo; Yong Wang; Yinmei Xia; Qin-Min Wang; Jifa Zhang; Lianhai ShanShow moreShow less
Affiliations
1. School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China; 2. Department of Neurology, Laboratory of Neuro-system and Multimorbidity, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaShow moreShow less
38
days
Enhancement of antitumor activity through structural optimization of 2-(Benzylamino)-thieno[2,3-d]pyrimidin-4(3H)-ones
Authors
Nazariy Pokhodylo; Kostiantyn Levchenko; Nataliya Finiuk; Yuliia Kozak; Olha Klyuchivska; Rostyslav StoikaShow moreShow less
Affiliations
1. Ivan Franko National University of Lviv, Lviv, Ukraine; 2. Institute of Cell Biology, National Academy of Sciences of Ukraine, Lviv, UkraineShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
